58 results
8-K
EX-1.1
CHRS
Coherus Biosciences Inc
25 May 18
Coherus Announces Proposed Public Offering of Common Stock
4:01pm
A, the “Pricing Disclosure Package”): a Preliminary Prospectus dated May 21, 2018 and each “free-writing prospectus” (as defined pursuant to Rule 405 under … Preliminary Prospectus has been issued by the Commission, and each Preliminary Prospectus included in the Pricing Disclosure Package, at the time
8-K
EX-1.1
CHRS
Coherus Biosciences Inc
18 May 23
Other Events
5:02pm
Package”): a Preliminary Prospectus dated May 16, 2023 and each “free-writing prospectus” (as defined pursuant to Rule 405 under the Securities Act … Prospectus has been issued by the Commission, and each Preliminary Prospectus included in the Pricing Disclosure Package, at the time of filing thereof
8-K
EX-99.1
CHRS
Coherus Biosciences Inc
31 Jul 18
Other Events
4:06pm
opinion issued by the CHMP today is a significant milestone for Coherus, as it validates both our UDENYCA biosimilarity package as well as our development … ) and pharmacodynamics (PD) study in healthy subjects, as well as a robust immunogenicity package including a dedicated immunogenicity study in over 300 subjects
8-K
EX-99.1
CHRS
Coherus Biosciences Inc
2 Nov 18
Other Events
4:05pm
expected demand for an extended period.”
The approval of UDENYCA™ was supported by a comprehensive analytical similarity package, as well … as pharmacokinetic, pharmacodynamic and immunogenicity studies, including over 600 healthy subjects.
“UDENYCA’s robust clinical package includes a dedicated
8-K
giubzrp rvy6
26 Dec 23
Other Events
8:49pm
S-1/A
ufeja9e70e5a1
6 Oct 14
IPO registration (amended)
12:00am
CORRESP
4zh83oj3m6u5boiar
15 Oct 19
Correspondence with SEC
12:00am
DRS/A
EX-10
4zwxtr46eymwrs
5 Aug 14
Draft registration statement (amended)
12:00am
DRS
EX-10.14
uafd8gkbixl
4 Aug 14
Draft registration statement
12:00am
DRS/A
EX-10
l1rd5icmerbz7bi7
5 Aug 14
Draft registration statement (amended)
12:00am